NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES
THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.
- Dr. Fabrice NAVARRO, New Deal Project Coordinator
THE PROJECT GOALS
THE PROJECT GOALS
The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.
Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference.
Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut
Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy.
THE PROJECT NEWS
IBD & Tea: what patients want to know when it comes to a clinical trial
Often, patients who live with Inflammatory Bowel Disease (IBD) do not respond to conventional drugs and are offered [...]
November New Deal Reads
Patient involvement in clinical research: why, when and how. Sacristán JA. Et al. Patient preference and adherence, volume [...]
IBD & Tea: Building trust in new treatments & understanding clinical trials
Tina Aswani Omprakash is an award-winning blogger, speaker and patient opinion leader who advocates for chronic illnesses and [...]
Small drugs – Big considerations: How New Deal researchers are overcoming the challenges of scaling-up a potential IBD nanomedicine
A great chef could create an outstanding dish that revolutionizes cuisine – every time they prepare the recipe [...]
THE PROJECT PARTNERS
THE PROJECT PARTNERS
